Patent ID: 8802107

Claim:
A method of producing a lyophilized formulation of a VEGF antagonist, comprising a step of subjecting to lyophilization a pre-lyophilized formulation, which comprises: (a) 5-50 mg/ml of a vascular endothelial growth factor (VEGF) antagonist, comprising the amino acids 27-457 of SEQ ID NO:4; (b) 5-25 mM of sodium phosphate buffer, pH about 5.8-7.0; (c) 0.01-0.15% of an organic co-solvent, selected from the group consisting of polysorbate, polythylene glycol (PEG) propylene glycol, and a combination thereof; and, (d) 1-10% of a stabilizing agent selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol, to generate a lyophilized formulation.